aibio
Mergers ·
MiMedx and Sanara MedTech receive FTC Second Request on merger
The request extends the antitrust waiting period until 30 days after the companies substantially comply. MiMedx says it is working constructively with the FTC.
MDXG MiMedx Group, Inc.
MiMedx Group (MDXG) news MDXG merger news
Latest MiMedx Group news
- Mergers
MiMedx and Sanara receive FTC Second Request on proposed merger
The request extends the antitrust waiting period until 30 days after the companies substantially comply. MiMedx says it is working constructively with the FTC.
What MiMedx Group does
MiMedx Group provides a portfolio of products for wound care, burn and surgical applications, built on placental tissue allografts. The company says its human-derived products start from donated birth tissue, namely the human placental membrane, umbilical cord and placental disc, which it sources through a donor network developed over more than a decade. Its primary areas of clinical use in the United States include surgical settings and the treatment of wounds, and to a lesser extent burns. Domestic sales account for the vast majority of its revenue. The company describes chronic wounds as affecting more than 10 million Medicare beneficiaries in the United States. Beginning in 2024, MiMedx broadened its portfolio to include animal-derived products, or xenografts, and in 2025 and early 2026 it entered into agreements with manufacturers of other wound care modalities. The company continues to pursue international expansion, primarily targeting Japan.
MiMedx Group annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $418.6 million | $348.9 million |
| Research and development | $15.1 million | $12.3 million |
| Net income (loss) | $48.6 million | $42.4 million |
| Cash from operations | $74.0 million | $66.2 million |
| Cash and equivalents | $166.1 million | $104.4 million |
Questions about MiMedx Group
Is MiMedx Group involved in a merger or acquisition?
Our latest story on this, dated Oct 16, 2026: "MiMedx and Sanara MedTech receive FTC Second Request on merger". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of MiMedx Group?
MiMedx Group, Inc. trades under the ticker MDXG on NASDAQ.
Where is MiMedx Group listed?
MiMedx Group, Inc. is listed on NASDAQ.
What is the SEC CIK of MiMedx Group?
The SEC Central Index Key (CIK) for MiMedx Group, Inc. is 1376339. Its filings are on SEC EDGAR.
How many shares does MiMedx Group have outstanding?
145,760,468 shares as of 2026-07-23, per the cover page of its 10-Q filed 2026-07-29.
Which country or territory is MiMedx Group listed under?
Our directory records MiMedx Group, Inc. under United States.
What does MiMedx Group do?
Our directory classifies MiMedx Group, Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline.
What is the ISIN of MiMedx Group?
The ISIN recorded for MiMedx Group, Inc. is US6024961012.
Does aibio.space cover MiMedx Group?
aibio.space lists MiMedx Group, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
What does MiMedx Group develop?
MiMedx Group provides a portfolio of products for wound care, burn and surgical applications, built on placental tissue allografts. The company says its human-derived products start from donated birth tissue, namely the human placental membrane, umbilical cord and placental disc, which it sources through a donor network developed over more than a decade.
What was MiMedx Group's revenue last year?
$418.6 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is MiMedx Group profitable?
MiMedx Group, Inc. reported net income of $48.6 million for the fiscal year ended Dec 31, 2025, and generated $74.0 million of cash from operations, per its annual report to the SEC.
How much does MiMedx Group spend on research and development?
$15.1 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does MiMedx Group have?
$120.8 million in cash at Sep 30, 2026, per its 10-Q.
What is the latest MiMedx Group (MDXG) stock news?
Our latest story on MiMedx Group, dated Oct 16, 2026: "MiMedx and Sanara MedTech receive FTC Second Request on merger". The request extends the antitrust waiting period until 30 days after the companies substantially comply. MiMedx says it is working constructively with the FTC. Source.
Investor discussion: MiMedx Group
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
Stock chart
SEC filings and registration
- SEC name
- Mimedx Group, Inc.
- CIK
- 1376339
- Industry (SIC)
- Surgical & Medical Instruments & Apparatus (3841)
- US tickers
- MDXG (Nasdaq)
- Fiscal year ends
- December 31
- Filer category
- Large accelerated filer
- Business address
- 1775 W OAK COMMONS COURT, NE, MARIETTA, GA, 30062
- Phone
- (770) 651-9100
- Shares outstanding
- 145,760,468 as of 2026-07-23 (10-Q filed 2026-07-29)
- Former names
- Alynx, Co.
Recent filings
Listing details
- Company
- MiMedx Group, Inc.
- Ticker
- MDXG
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Biopharma / pharmaceuticals
- ISIN
- US6024961012
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction